Hypertrophy: Clinical Trials

8 trials for Hypertrophy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed. 8 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 18Completed 8
Phase 22Completed 2

Follow Hypertrophy: new trials by email Literature Review of Hypertrophy trials Research Report on Hypertrophy

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Effects of Mavacamten in Healthy Participants
Mavacamten - Healthy Participants
Phase 1CompletedBristol-Myers Squibb842023-02-202023-10-12
MPN-RC 118 AVID200 in Myelofibrosis
AVID200 - Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Phase 1CompletedJohn Mascarenhas212019-02-152023-02-10
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
Laboratory Biomarker Analysis, Metformin Hydrochloride, Pharmacological Study - Anemia, Fatigue
Phase 1CompletedCity of Hope Medical Center32017-09-072026-10-19
High Fluence Light Emitting Diode-Red Light (LED-RL) in Human Skin
LED-RL Phototherapy, Mock Therapy - Fibrosis, Scarring
Phase 1CompletedJared Jagdeo, MD, MS602016-01-012017-03-31
Valproic Acid (Depakote[Registered Trademark]) to Treat Autoimmune Lymphoproliferative Syndrome (ALPS)
Valproic Acid, CT Scan, Blood Sample - ALPS, Hypersplenism
Phase 1 / Phase 2CompletedKoneti Rao62008-01-012013-03-21
Resistance Training in Elderly
protein drink, Resistance training - Sarcopenia, Atrophy
Phase 1 / Phase 2CompletedMaastricht University Medical Center262007-01-012015-09-23
Pyrimethamine to Treat Autoimmune Lymphoproliferative Syndrome
Pyrimethamine - Autoimmune Disease, Lymphatic Disease
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)82003-07-012008-03-04
Pyrimethamine and Sulfadoxine for Treatment of Autoimmune Lymphoproliferative Syndrome
Fansidar (pyrimethamine and sulfadoxine) - Autoimmune Disease, Lymphoproliferative Disorder
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)82001-03-012008-03-04

Narrower conditions

Splenomegaly (5)  ·  Lymphadenopathy (4)  ·  Autoimmune Lymphoproliferative Syndrome (3)  ·  Autoimmune Diseases (2)  ·  Fibrosis (2)  ·  Lymphoproliferative Disorders (2)  ·  Anemia (1)  ·  Atrophy (1)  ·  Cardiomyopathy, Hypertrophic (1)  ·  Cardiovascular Diseases (1)  ·  Cicatrix (1)  ·  Fatigue (1)  ·  Fever (1)  ·  Heart Diseases (1)

Broader conditions

Pathological Conditions, Anatomical (8)  ·  Pathological Conditions, Signs and Symptoms (8)  ·  Hemic and Lymphatic Diseases (5)  ·  Immune System Diseases (4)  ·  Immunoproliferative Disorders (4)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3)  ·  Genetic Diseases, Inborn (3)  ·  Lymphatic Diseases (3)  ·  Pathologic Processes (3)  ·  Hematologic Diseases (2)  ·  Lymphoproliferative Disorders (2)  ·  Signs and Symptoms (2)  ·  Aortic Stenosis, Subvalvular (1)  ·  Aortic Valve Disease (1)

Interventions

Pyrimethamine (2)  ·  Blood Specimen Collection (1)  ·  MYK-461 (1)  ·  Metformin (1)  ·  Quality of Life (1)  ·  Resistance Training (1)  ·  Ritonavir (1)  ·  Sulfadoxine (1)  ·  Surveys and Questionnaires (1)  ·  Valproic Acid (1)  ·  fanasil, pyrimethamine drug combination (1)

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID) (2)  ·  Bristol-Myers Squibb (1)  ·  City of Hope Medical Center (1)  ·  Jared Jagdeo, MD, MS (1)  ·  John Mascarenhas (1)  ·  Koneti Rao (1)  ·  Maastricht University Medical Center (1)

Countries

United States (7)  ·  Netherlands (1)

Top investigators

Jared Jagdeo, MD, MS (1)  ·  John Mascarenhas, MD (1)  ·  Koneti Rao, MD (1)  ·  Luc JC van Loon, PhD (1)  ·  Nitya Nathwani, MD (1)  ·  Ronald Hoffman, MD (1)  ·  Ruben Mesa, MD (1)

Results publications

PMID 18459515, PMID 19106243, PMID 19146602, PMID 23077622, PMID 23590233, PMID 25485805, PMID 27484782, PMID 40643151

NIH funding

P01CA108671 (1)